A series of organometallic half-sandwich dichloridoruthenium(II) complexes of the general formula [Ru(η 6 -p-cym)(naza)Cl 2 ] (1-8; p-cym = p-cymene; naza = 7-azaindole or its derivatives) was synthesised and fully characterized by elemental analysis, mass spectrometry, and infrared and multinuclear NMR spectroscopy. A single-crystal X-ray structural analysis of [Ru(η 6 -p-cym)(2Me4Claza)Cl 2 ] (6) revealed a typical piano-stool geometry with an N7-coordination mode of 2-methyl-4-chloro-7-azaindole (2Me4Claza). The complexes have been found to be inactive against human ovarian cancer cell line A2780 up to the highest applied concentration (IC 50 > 50.0 μM). An inactivity of the complexes is caused by their instability in water-containing solvents connected with a release of the naza N-donor ligand, as proved by the detailed 1 H NMR, mass spectrometry and fluorescence experiments.
Introduction
Platinum-based anticancer agents (e.g. cisplatin, oxaliplatin and carboplatin) are widely used for treating of various types of cancer [1] [2] [3] . However, their clinical utility is limited because many tumors are resistant to the platinum drugs and these cytostatics show several side effects including neurotoxicity, nephrotoxicity or myelosuppression. These drawbacks motivate bioinorganic chemists to development of complexes based on other, i.e. non-platinum, transition metals, which would offer wide range of anticancer efficacy and show reduced negative side effects. Among these compounds, the ruthenium-based antitumor agents represent a promising alternative to the clinically used platinum(II) compounds showing different mechanism of action connected with high cytotoxicity, different spectrum of efficiency against human cancer cell lines and the prospect of non cross-resistance [3] [4] [5] [6] [7] . Two ruthenium compounds, KP1019/ NKP-1339 (indazolium or sodium salt of trans-[RuCl 4 (ind) 2 ]; ind = indazole) and NAMI-A ((imH)[trans-RuCl 4 (DMSO)(im)]; im = imidazole), recently entered the clinical trials as prospective anticancer agents [8, 9] . Many other ruthenium complexes were found to be highly in vitro and/or in vivo antitumor active against various types of tumors [10, 11] . For example, complex [Ru(η 6 -p-cym)(L 1 )Cl](PF 6 ) was tested in vitro against ovarian A2780 (IC 50 = 16.2 μM), lung A549 (IC 50 = 10.5 μM), colon HCT116 (IC 50 = 3.4 μM) and breast (IC 50 = 12.1 μM) carcinoma human cancer cell lines; L 1 = N,N-dimethyl-N-[(2-pyridinyl)methylene]-1,4-benzenediamine [10] . Another Ru complex, trans-[RuCl 4 (DMSO)(L 2 )]ÁMe 2 CO, showed significantly higher (p < 0.05) in vivo antitumor activity against lymphocytic leukaemia L1210 (% T/C = 106) in comparison with aforementioned NAMI-A (% T/C = 94); L 2 = 6-(2-bromobenzylamino)purine; % T/C is defined as the ratio of the mean survival time of the treated animal groups (T) divided by the mean survival of the untreated control group (C) [11] .
Half-sandwich organometallic ruthenium(II) complexes offer a broad scope for the design of therapeutic and diagnostic agents [10, 12] . These complexes have attracted considerable interest as potential anticancer agents because of their efficacy against platinum drug-resistant tumors, selectivity and often good aqueous solubility. A representative of this group is a dichloridoruthenium(II) complex RAPTA-C, [Ru(η 6 -p-cym)(pta)Cl 2 ] (Fig 1 ; pta = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane), showing strong angiogenic effect [13] . Various RAPTA-C analogues of the general composition [Ru(η 6 -p-cym)(L)Cl 2 ] containing a monodentate-coordinated N-donor ligand (L) have been reported to date as being in vitro cytotoxic against various human cancer lines [14] [15] [16] [17] [18] [19] [20] [21] [22] . In particular, complex containing lonidamine-modified imidazole ligand exhibited IC 50 values of 19.3, 17.9, 6.4, 8.3, 5.7, 20 .5 and 20.2 μM against human cisplatin-sensitive (A2780) and -resistant (A2780R) ovarian cancer cell lines, human glioblastoma cell lines LN18, LN229, LNZ308, non-cancerous HEK cell line, and cortex neurons, respectively [14] . [Ru(η 6 -p-cym)(L 3 )Cl 2 ], where L 3 = 4-[(10-hydroxydecyl) oxy]phenyl-4-pyridinecarboxylate, was found to be highly active against A2780 and A2780R (IC 50 = 0.2 μM, and 3.0 μM, respectively) [15] . The complex [Ru(η 6 -p-cym)(L 4 )Cl 2 ] with 3-aza-5H-phenanthridin-6-one (L 4 ) acting as monodentate N-donor ligand was moderately in vitro cytotoxic against human A549 lung, HCT116 colon, A2780 ovarian and Hcc1937 breast carcinoma cell lines, as well as against MRC5 normal lung fibroblast cell line with the IC 50 values equalled 85.1, 38.8, 46.0, 93.3 and 143.0 μM, respectively [16] . 
Materials and Methods

Chemicals
The chemicals (RuCl 3 ÁxH 2 O, 7-azaindole (aza), 3-iodo-7-azaindole (3Iaza), 3-chloro-7-azaindole (3Claza), 5-bromo-7-azaindole (5Braza), 5-fluoro-7-azaindole (5Faza), 2-methyl-4-chloro-7-azaindole (2Me4Claza), 3-chloro-5-bromo-7-azaindole (3Cl5Braza), 3-iodo-5-bromo-7-azaindole -p-cym)Cl] 2 was prepared according to the reported synthetic procedure [23] .
Synthesis
[Ru(μ-Cl)(η 6 -p-cym)Cl] 2 (0.1 mmol, 61.2 mg) was dissolved in methanol (5 mL) and left to react with two molar equivalents of the corresponding naza. The reaction mixture was stirred at ambient temperature for 20 min (reactions with 5Braza and 5Faza), 2 h (reactions with aza, 3Iaza and 3Claza) or 3 h (reactions with 2Me4Claza, 3Cl5Braza and 3I5Braza), until the yellow (for 2, 4 and 5), or light (for 8) or dark (for 1, 3, 6 and 7) orange product was formed. The products (Fig 1) were isolated by filtration, washed with methanol (2 × 2 mL) and diethyl ether (3 × 5 mL) and dried under the infrared lamp (40°C, 4 h). The yields were 60-80%.
[ Single-crystal X-ray analysis of [Ru(η 6 -p-cym)(2Me4Claza)Cl 2 ] (6)
Single crystals of [Ru(η 6 -p-cym)(2Me4Claza)Cl 2 ] (6) were grown from its saturated MeOH solution by slow evaporation method after 48 h of standing at ambient temperature. X-ray diffraction data of 6 were collected with a Rigaku HighFlux HomeLab™ universal dual wavelength (Mo-Kα and Cu-Kα) single crystal diffractometer at 120(2) K, using the Mo-Kα radiation (λ = 0.71075 Å). The diffractometer was equipped with the Eulerian 3 circle goniometer and the Rigaku Saturn724+ (2 × 2 bin mode) detector. Data reduction and correction of the absorption effect were performed using the XDS software package [24] . The structure was solved by direct methods using SHELXS and refined on F 2 using the full-matrix least-squares procedure (SHELXL) [25] . Non-hydrogen atoms were refined anisotropically and all H-atoms were found from difference Fourier maps and refined using a riding model, with the AFIX 14, AFIX 43 and AFIX 137 instructions. X-ray crystallographic data for 6 have been deposited in the Cambridge Structural Database under the accession Cambridge Crystallographic Data Centre number CCDC 1416250. The crystal data and structure refinements are given in S1 Table. The molecular graphics were drawn and additional structural calculations were interpreted using DIAMOND [26] and Mercury [27] .
Cell culture and in vitro cytotoxicity testing
The in vitro cytotoxicity towards human ovarian carcinoma A2780 (ECACC No. 93112519) was tested by an MTT assay evaluated spectrophotometrically at 540 nm (TECAN, Schoeller Instruments LLC). The cancer cell lines were cultured according to the ECACC instructions and were maintained at 37°C and 5% CO 2 in humidified incubator. 1-8, cisplatin and naza (0.01-50.0 μM concentrations) interacted with the cancer cells for 24 h, using 96-well culture plates. The cells was tested in parallel with vehicle (DMF; 0.1%, v/v), and Triton X-100 (1%, v/ v) to assess the minimal (100% viability) and maximal (0% viability) cell damage, respectively. The cytotoxicity data were received from three independent experiments (each conducted in triplicate) using cells from three consecutive passages. Fluorescence quenching experiments ctDNA (154 μM) and EtBr (3 mM) were mixed together in TRIS/NaCl buffer (pH = 7.2) and incubated for 30 min at ambient temperature. 0, 100, 200, 400, 600 and 1000 μL of the representative complexes 2, 5 and 8 (stock solutions of the 150 μM concentration) dissolved in 10% methanol solution in TRIS/NaCl buffer were added to the EtBr/ctDNA system and the volume was refilled to 3 mL with TRIS/NaCl buffer. The mixtures were incubated at ambient temperature for next 15 min. The emitted fluorescence (546 nm excitation wavelength) was recorded on a fluorescence spectrometer AvaSpec HS1024x122TE using a 1 cm quartz cell.
Studies of solvolysis and interactions with glutathione (GSH)
The
Results and Discussion
This work aimed to prepare and study the in vitro cytotoxicity and basic mechanistic aspects of half-sandwich organometallic dichloridoruthenium(II) complexes of the general formula [Ru (η ligands. Many representatives of this type of ruthenium(II) organometallic complexes have been recently reported by several research groups as antitumor active against various human cancer cell lines (see Introduction) [14] [15] [16] [17] [18] [19] [20] [21] [22] . In the case of this work, the 7-azaindole or its derivatives were used, because these simple organic compounds were recently shown as suitable monodentate N-donor ligands of biologically active transition metal complexes, such as cis-dichloridoplatinum(II) complexes (e.g. references [28] [29] [30] -p-cym)(naza)Cl 2 ] (1-8; Fig 1) was prepared by a one-step synthesis using the reaction of the stoichiometric amounts of the [Ru(μ-Cl)(η 6 -p-cym)Cl] 2 dimer and appropriate naza, as -22] . The reaction time differed depending on the substituent position on the 7-azaindole moiety. In particular, 4 and 5 containing 5-monosubstituted 7-azaindoles formed almost immediately and were isolable after 20 min of stirring at ambient temperature. For the complexes 1-3 and 6-8, the reaction time was longer (2 or 3 h), because product formed gradually during this period of time. The complexes 1-8 were obtained in the yields of ca 60-80% (related to the starting Ru(II) dimer) and their composition and chemical purity were proved by a combination of elemental analysis, 1 H NMR spectroscopy in CDCl 3 (Fig 2) and a single-crystal X-ray structural analysis.
All the signals of the coordinated p-cymene and 7-azaindole-based ligands were found in The ESI+ mass spectra were recorded on MeOH solutions of 1-8. The peaks of the monochlorido [Ru(η 6 -p-cym)(naza)Cl] + species were found for 1-6 and 8 (see S1 Fig for 8 the peaks detected also in the spectra of the starting ruthenium(II) dimer (S2 Fig). Finally, the ESI+ mass spectra of 1-8 also contained the peaks of {(naza)+H} + corresponding to the free naza species.
Molecular and crystal structure of 6. The crystals of [Ru(η 6 -p-cym)(2Me4Claza)Cl 2 ] (6) suitable for a single-crystal X-ray analysis were prepared by a diffusion of diethyl ether into the saturated chloroform solution of 6. The molecular and crystal structures are depicted in Fig 3,  and S3 Fig, respectively , while the selected bond lengths and angles can be found in Table 1 . The complex 6 adopts the pseudo-octahedral piano-stool geometry (Fig 3) known to be typical for the structural analogues. To date, forty four half-sandwich p-cymene-dichloridoruthenium(II) complexes containing various heterocyclic ligands coordinated through endocyclic sp 2 [21] .
The Ru(II) atom of 6 is η 6 -π-bonded to the arene ring of p-cymene, and coordinated by two chlorido ligands and one 2Me4Claza molecule monodentate-coordinated to the metal centre through the pyridyl nitrogen (N7). An N7-coordination mode of 2Me4Claza is consistent with the formerly reported ruthenium(II) complexes [Ru 2 (μ-L 10 ) 4 [19] . The dihedral angle formed by the aromatic ring of p-cymene and 7-azaindole moiety is 29.98(4°.
The crystal structure involves intramolecular N1-HÁÁÁCl2 hydrogen bond with d (N1ÁÁÁCl2) = 3.030(2) Å and <(N1-HÁÁÁCl2) = 135.36(12° (Fig 3) , and several intermolecular non-covalent contacts of the C-HÁÁÁCl, C-HÁÁÁC and CÁÁÁCl type (S2 Table, S3 Fig) . Interestingly, no intermolecular π-π stacking interactions were found in the crystal structure of 6. 
Studies of in vitro cytotoxicity and related mechanistic aspects
In vitro cytotoxicity against the A2780 cell line. All the prepared complexes were studied for their in vitro cytotoxicity against A2780 ovarian carcinoma cells, known to be sensitive for analogical organometallic dichloridoruthenium(II) complexes [14] [15] [16] [17] . For example, structurally similar [Ru(η 6 -p-cym)(L)Cl 2 ] complexes containing lonidamine-modified imidazole -p-cym)(2Me4Claza)Cl 2 ] (6). Non-hydrogen atoms are drawn as thermal ellipsoids at the 50% probability level and hydrogen atoms, except for the N1-H hydrogen involved in the depicted intramolecular N1-HÁÁÁCl2 hydrogen bond (red dashed line), were omitted for clarity. p-cym = p-cymene, 2Me4Claza = 2-methyl-4-chloro-7-azaindole. [17] were recently reported as highly active against the A2780 cell line. However, all the studied complexes 1-8 were found to be inactive up to the highest tested concentration (IC 50 > 50.0 μM).
With respect to the aforementioned findings regarding the mutually different in vitro cytotoxicity of 1-8 against A2780, as compared with their analogues containing different monodentate N-donor ligands [14] [15] [16] [17] , we decided to perform several relevant experiments ( 1 H NMR, ESI+ mass spectrometry), designed to shed a light on the reasons of inactivity of 1-8 (studied for the representative complexes 2 and 8). The experiments were designed to prove whether: 1/ the complexes are stable under the used experimental condition and inactivity is due to low sensitivity of the A2780 cells towards 1-8 (in this case, different cancer cell line could be used); and 2/ the complexes are unstable under the experimental condition used and thus unsuitable for further biological studies.
H NMR spectroscopy of complexes 2 and 8 in DMF-d 7
The reason why a pure DMF-d 7 was utilized for the stability study is that this solvent is typically used for the pre-dissolution (and consequently, the DMF-d 7 solution is diluted by medium to a maximal DMF concentration of 0.1%) of the corresponding complex during the cytotoxicity testing. Logically, it was of a great interestto find out if the composition of the complexes can be affected by this solvent. to the naza and p-cymene ligands, which revealed at 7.75/5.78/5.49 ppm (for 2) and 7.48/5.99/ 5.87 ppm (for 8), may be associated with the formation of decomposition products, probably connected with the solvolysis (substitution of the chlorido ligand(s) with DMF). This finding is, in the case of 8, supported by an increasing portion of this impurity from < 5% in the fresh DMF-d 7 solution to ca 20% after 48 h (Fig 4) . , were not detected, it is evident from the ESI+ mass spectrometry results that the complex 2 is decomposed to various species.
Addition of D 2 O into the DMF-d 7 solution of 8 led to the formation of white precipitate which was centrifuged, and the isolated solid was dissolved in DMF-d 7 and proved to be free 3I5Braza by 1 H NMR experiment. After removing of the precipitate, the 1 H NMR spectrum of 8 showed, in total, four pairs of doublets belonging to C13,15-H 2 /C12,16-H 2 detected at 5.51/ 5.31, 5.64/5.44, 5.95/5.75 and 6.10/5.87 ppm, with the integral intensities being 0.18, 0.15, 1.00, and 1.00, respectively (Fig 4) . No 3I5Braza signals were found in the appropriate proton spectra. In other words, addition of D 2 O into the DMF-d 7 solution of 8 led to its complete decomposition connected with a release of 3I5Braza (Fig 4) . Similarly to 2, the mass spectrum of 8 dissolved in 10% DMF/H 2 O revealed [Ru 2 (η 6 -p-cym) 2 O) led to the release of naza and the formation of low active or most probably non-potent ruthenium-containing species. Since the used mixture of solvents was similar to that one used for in vitro cytotoxicity testing (0.1% DMF in RPMI-1640 medium), it can be anticipated that similar processes proceeded within the performed biological testing, altogether resulting in inactivity of the studied complexes against the used human cancer cell line.
1 H NMR spectroscopy of complexes 2 and 8 in MeOD-d 4
Since it was observed that the studied complexes are stable in CDCl 3 (see section Chemistry, Fig 2, with a coordination ability index of -2.2) and unstable in DMF-d 7 (see above, with a coordination ability index of -0.2), as judged by 1 H NMR spectra, we strived to investigate their solution behaviour also in another relevant solvent (i.e. methanol), with a coordination ability of -0.4 [34] . (Fig 4) . These signals pointed out the fact that both the p-cymene and naza ligands are present in both the complex species. Moreover, another set of the naza signals was also found in the spectra of both 2 and 8. The position of the C2-H signal is consistent with the free 3Claza, as proved for 2 (7.42 ppm). However, the same could not be proved in the case of complex 8 because it contains 3I5Braza which is insoluble in methanol. This indicated that the mentioned set of the 3I5Braza signals detected in the MeOD-d 4 solution of 8 most probably did not belong to a released 3I5Braza but to a complex containing the mentioned ligand. Moreover, in the case of 8, another pair of p-cymene aromatic hydrogen atom signals (i.e. C13,15-H 2 /C12,16-H 2 ) was observed at 5.79/5.54 ppm, but it was not accompanied by the appropriate signals (C2-H) at the 3I5Braza region (Fig 4) . Overall, the individual signals of the spectra as well as their integral intensities did not change in time up to 48 h of standing at ambient temperature for both 2 and 8 (Fig 4, S4 Fig) . Thus, it could be concluded that at least a part of the complexes 2 and 8 decomposed in MeOD-d 4 together with the release of naza, which correlates well with the mass spectrometry results obtained for MeOH solutions of the studied complexes, as discussed above. (Fig 4) . Both these pairs of doublets correlated with those of the starting ruthenium(II) dimer in 10% MeOD-d 4 /D 2 O (an integral intensity ratio of 1.0: 0.2). On the other hand, any C2-H signals were not detected at the 3I5Braza region for 8. [35] . With respect to the above mentioned findings, it is evident that most of the studied complex 2 decomposed leading to the formation of an Ru-containing adduct with the deprotonated glutathione coordinated through the S-atom (Ru-SG). An integral intensity of the signals of the Ru-SG adduct was not consistent with the above mentioned p-cymene signals, proving that the Ru-SG adduct does not contain neither p-cymene nor 3Claza ligand. Interestingly, a ratio of Cys-α and Cys-β signals of free and coordinated glutathione (1: 9 for the fresh solution, as mentioned above) changed to ca 1: 1 after 48 h of standing at the ambient temperature, meaning that the formed Ru-SG adduct is unstable in the used mixture of solvents, which is connected with a release of GSH. -p-cym)(L)Cl 2 ] should show anticancer activity, as can be seen from references [14] [15] [16] [17] reporting the complexes of the mentioned general formula potent against A2780 ovarian carcinoma cells used also in this work. 
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